AbbVie Inc. $ABBV Stock: First Citizens Bank & Trust Co. Increases Position

First Citizens Bank & Trust Co. raised its holdings in shares of AbbVie Inc. (NYSE:ABBV) by 25.4% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 54,546 shares of the company’s stock after purchasing an additional 11,032 shares during the period. First Citizens Bank & Trust Co.’s holdings in AbbVie were worth $14,269,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of ABBV. Corient Private Wealth LP bought a new position in shares of AbbVie during the second quarter valued at approximately $559,736,000. Legal & General Group Plc bought a new position in AbbVie in the second quarter worth about $2,905,952,000. Jupiter Topco LLC bought a new position in AbbVie in the second quarter worth about $1,560,354,000. Diamant Asset Management Inc. lifted its holdings in AbbVie by 21,649.0% in the first quarter. Diamant Asset Management Inc. now owns 3,671,231 shares of the company’s stock worth $798,456,000 after buying an additional 3,654,351 shares during the period. Finally, Canada Pension Plan Investment Board purchased a new stake in AbbVie in the second quarter worth about $817,473,000. Hedge funds and other institutional investors own 70.23% of the company’s stock.

Insider Transactions at AbbVie

In other AbbVie news, EVP Nicholas Donoghoe sold 32,710 shares of AbbVie stock in a transaction that occurred on Friday, August 14th. The shares were sold at an average price of $250.00, for a total value of $8,177,500.00. Following the completion of the sale, the executive vice president owned 74,430 shares of the company’s stock, valued at approximately $18,607,500. The trade was a 30.53% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Corporate insiders own 0.06% of the company’s stock.

AbbVie Price Performance

Shares of AbbVie stock opened at $274.82 on Wednesday. AbbVie Inc. has a 1 year low of $190.75 and a 1 year high of $283.43. The firm’s 50-day moving average is $260.41 and its 200 day moving average is $237.87. The stock has a market cap of $485.55 billion, a price-to-earnings ratio of 77.63, a PEG ratio of 1.28 and a beta of 0.24.

AbbVie (NYSE:ABBV) last issued its earnings results on Friday, July 31st. The company reported $3.65 earnings per share for the quarter, topping analysts’ consensus estimates of $3.61 by $0.04. The business had revenue of $16.99 billion during the quarter, compared to analyst estimates of $16.80 billion. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%. AbbVie’s revenue was up 10.2% on a year-over-year basis. During the same quarter in the previous year, the firm earned $2.97 EPS. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. On average, equities analysts expect that AbbVie Inc. will post 13.95 EPS for the current fiscal year.

AbbVie Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, November 16th. Investors of record on Thursday, October 15th will be given a dividend of $1.73 per share. The ex-dividend date is Thursday, October 15th. This represents a $6.92 dividend on an annualized basis and a yield of 2.5%. AbbVie’s dividend payout ratio is 195.48%.

Analyst Ratings Changes

Several analysts have weighed in on ABBV shares. Wolfe Research raised AbbVie from a “peer perform” rating to an “outperform” rating and lifted their price objective for the company from $235.00 to $300.00 in a research report on Thursday, August 13th. Leerink Partners increased their target price on AbbVie from $245.00 to $279.00 and gave the stock an “outperform” rating in a research report on Wednesday, August 5th. Weiss Ratings upgraded shares of AbbVie from a “buy (b-)” rating to a “buy (b)” rating in a report on Thursday, October 8th. Erste Group Bank raised shares of AbbVie from a “hold” rating to a “buy” rating in a research report on Wednesday, August 5th. Finally, JPMorgan Chase & Co. boosted their price objective on shares of AbbVie from $285.00 to $300.00 and gave the stock an “overweight” rating in a research note on Thursday, October 8th. One research analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and six have issued a Hold rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $277.18.

Key AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Potential Q3 revenue beat: RBC expects AbbVie to exceed third-quarter revenue estimates, driven by continued momentum for immunology drugs Skyrizi and Rinvoq, as well as psychiatric medicine Vraylar. This supports expectations that newer products can offset Humira’s loss of exclusivity. AbbVie Poised for Q3 Top-Line Beat Driven by Rinvoq, Skyrizi, and Vraylar Therapies, RBC Says
• Positive Sentiment: Encouraging Skyrizi data: New Phase 3 AFFIRM results showed favorable clinical and endoscopic outcomes for subcutaneous Skyrizi in patients with moderately to severely active Crohn’s disease. The data could strengthen Skyrizi’s position in a major growth market and expand AbbVie’s immunology opportunity. AbbVie Presents New Phase 3 AFFIRM Data
• Positive Sentiment: Pipeline and analyst support: Recent Crohn’s disease data for Skyrizi and Rinvoq, cancer-related regulatory milestones for Temab-A, and early metabolic-treatment data are improving the outlook for AbbVie’s post-Humira growth. RBC reaffirmed its “Outperform” rating, although its target implies only limited additional upside. AbbVie Could Be 44% Below Fair Value on Fresh Pipeline Wins
• Neutral Sentiment: Strategic expansion: AbbVie’s acquisition of Apogee and related leadership moves highlight the company’s effort to replenish its pipeline through business development, but the long-term financial impact remains uncertain. Biotech Builder Paragon Imports Apogee’s Top Brass After AbbVie Buyout
• Negative Sentiment: Valuation and execution risks: At a high earnings multiple near its recent peak, ABBV may be vulnerable to profit-taking even with positive clinical news. Investors also remain concerned about Humira’s ongoing sales erosion, increasing immunology competition, and whether Skyrizi and Rinvoq can sustain their rapid growth.

AbbVie Company Profile

AbbVie Inc is a global biopharmaceutical company that develops, manufactures and markets medicines for a range of serious and chronic health conditions. Its portfolio spans immunology, oncology, neuroscience, eye care, aesthetics, gastroenterology and women’s health.

The company’s products include the immunology medicines Skyrizi and Rinvoq; neuroscience treatments such as Vraylar, Ubrelvy and Qulipta; and oncology medicines including Imbruvica and Venclexta. AbbVie also markets Botox Cosmetic and Botox Therapeutic, as well as other products for aesthetics, eye care and specialty care.

AbbVie was established in 2013 as an independent, publicly traded company following its separation from Abbott Laboratories.